The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Open accessAbstract
BACKGROUND: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. METHODS: We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) or standard care and to receive n-3 fatty acids or placebo with the use of a 2-by-2 factorial design. The results of the comparison between insulin glargine and standard care are reported here. The coprimary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. RESULTS: The median follow-up was 6.2 years (interquartile range, 5.8 to 6.7). Rates of incident cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85 per 100 person-years, respectively, for the first coprimary outcome (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P=0.63) and 5.52 and 5.28 per 100 person-years, respectively, for the second coprimary outcome (hazard ratio, 1.04; 95% CI, 0.97 to 1.11; P=0.27). New diabetes was diagnosed approximately 3 months after therapy was stopped among 30% versus 35% of 1456 participants without baseline diabetes (odds ratio, 0.80; 95% CI, 0.64 to 1.00; P=0.05). Rates of severe hypoglycemia were 1.00 versus 0.31 per 100 person-years. Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standard-care group. There was no significant difference in cancers (hazard ratio, 1.00; 95% CI, 0.88 to 1.13; P=0.97). CONCLUSIONS: When used to target normal fasting plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both insulin glargine U100 and insulin degludec have demonstrated cardiovascular safety in dedicated CVOTs (207,208).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [208]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“ORIGIN reported a 1.6 kg gain over 6 years with insulin glargine [46].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [46]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Modest survival benefits also have been reported for breast, ovarian, endometrial, prostate, lung, kidney, liver, and earlier stage pancreatic cancers.1791–1800”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1800]
Experimental — accuracy not yet measuredIn the citing paper
“The following drug classes were excluded due to lack of current evidence of efficacy in cardiovascular outcome trials: dipeptidyl peptidase-4 inhibitors,19 sulfonylureas,20 and insulin.21,22”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [21]
In the citing paper
“It is associated with a lower risk of death and HF hospitalization compared with insulin and sulphonylureas in observational studies, though dedicated randomized, controlled, CVOTs evaluating safety and efficacy of metformin have not been conducted.[555][556][557]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [555]
In the citing paper
“It is associated with a lower risk of death and HF hospitalization compared with insulin and sulphonylureas in observational studies, though dedicated randomized, controlled, CVOTs evaluating safety and efficacy of metformin have not been conducted.[555][556][557]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [555]
In the citing paper
“These trials have more or less uniformly demonstrated a benefit, with lifestyle more efficacious than all medications with the exception of the thiazolidinediones140–152.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [146]
In the citing paper
“In the only RCT of insulin vs. placebo [ORIGIN, 12 537 people with CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or T2DM (i.e.not in patients with HF)], insulin was not associated with higher rates of HF hospitalization than placebo.187”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [187]
In the citing paper
“Lowering glucose without addressing the vascular effects of insulin resistance may be insufficient to reduce risk of cardiovascular events.”
From The Vasculature in Prediabetes (2018) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Flagged first, then by citations
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 801–900 of 999
Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach
Johansen, O. E. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i9.1092 · Cited by 11
Management of Type 2 Diabetes Mellitus
Salti, I. S. (2014) · The Endocrine Society eBooks · doi:10.1210/mtp3.9781936704835.ch16 · Cited by 11
Individual Fatty Acids in Cardiometabolic Disease
Chowdhury, R., Steur, M., Patel, P. S., & Franco, O. H. (2016) · Elsevier eBooks · doi:10.1016/b978-1-63067-036-8.00010-x · Cited by 13
Long-term studies of treatments for type 2 diabetes
Caballero, A. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2017.1265417 · Cited by 10
Heart failure and diabetes: The confrontation of two major epidemics of the 21st century
Formiga, F., Camafort, M., & Carrasco-Sánchez, F. J. (2019) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.01.014 · Cited by 11
Creating Composite Indices From Continuous Variables for Research: The Geometric Mean
Gerstein, H. C., Ramasundarahettige, C. F., & Bangdiwala, S. I. (2021) · Diabetes Care · doi:10.2337/dc20-2446 · Cited by 11
Cardiovascular Outcome Trials with Glucose-Lowering Drugs
Thethi, T. K., Bilal, A., & Pratley, R. E. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01505-3 · Cited by 11
Hunt, L. M., Arndt, E., Bell, H. S., & Howard, H. (2021) · Journal of Bioethical Inquiry · doi:10.1007/s11673-021-10119-x · Cited by 12
Sherlock, L., Lee, S. F., Katsanos, A. H., Cukierman‐Yaffe, T., Canavan, M. D., Joundi, R. A., Sharma, M., Shoamanesh, A., Brayne, C., Gerstein, H. C., et al. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00207-6 · Cited by 11
Arm and ankle blood pressure indices, and peripheral artery disease, and mortality: a cohort study
Mohammedi, K., Pigeyre, M., Bosch, J., Yusuf, S., & Gerstein, H. C. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae087 · Cited by 11
Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus
Bethel, M. A., Xu, W., & Theodorakis, M. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12401 · Cited by 12
Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism
Redwan, E. M. M. M., Linjawi, M. H., & Uversky, V. N. (2016) · Scientific Reports · doi:10.1038/srep23320 · Cited by 11
Historique des études cardiovasculaires : de l’UGDP… aux dernières études
Scheen, A. J. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30053-6 · Cited by 11
Weak bones in diabetes mellitus – an update on pharmaceutical treatment options
Lin, D., & Dass, C. R. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12808 · Cited by 11
Srivastava, P. K., Pradhan, A. D., Cook, N. R., Ridker, P. M., & Everett, B. M. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007268 · Cited by 11
Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes?
Buse, J. B., D’Alessio, D. A., & Riddle, M. C. (2018) · Diabetes Care · doi:10.2337/dci18-0025 · Cited by 11
The past decade in type 2 diabetes and future challenges
HADDAD, J. A., & Haddad, A. N. (2018) · HORMONES · doi:10.1007/s42000-018-0080-y · Cited by 11
Conde, A. C., Martín, D. M., Arrarte, V., Campuzano, R., Dalmau, R., Olmo, M. R. F., García–Moll, X., Gómez‐Doblas, J. J., Gorgojo, J. J., Mazón, P., et al. (2019) · REC CardioClinics · doi:10.1016/j.rccl.2019.04.005 · Cited by 11
Gourdy, P., Bahloul, A., Boultif, Z., Gouet, D., & Guerci, B. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00734-8 · Cited by 11
Rigato, M., Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa178 · Cited by 14
Huang, W.-C., Chen, Y., Wu, C., & Ko, Y. (2021) · Scientific Reports · doi:10.1038/s41598-020-80753-9 · Cited by 11
Schroeder, E. B., Neugebauer, R. S., Reynolds, K., Schmittdiel, J. A., Loes, L., Dyer, W., Pimentel, N., DESAI, J. R., Vazquez‐Benitez, G., Ho, P. M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.26605 · Cited by 11
New Insulins and Insulin Therapy
Danne, T., & Bolinder, J. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.1505 · Cited by 11
Examining the Role of Insulin in the Regulation of Cardiovascular Health
Salt, I. P. (2012) · Future Cardiology · doi:10.2217/fca.12.77 · Cited by 11
Danne, T., Becker, R. H. A., Ping, L., & Philotheou, A. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12161 · Cited by 11
All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine
Strandberg, A. Y., Hoti, F. J., Strandberg, T. E., Christopher, S., Haukka, J. K., & Korhonen, P. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151910 · Cited by 11
rDNA insulin glargine U300 – a critical appraisal
Wang, F., Zassman, S., & Goldberg, P. A. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s87873 · Cited by 11
Insulin resistance and cardiovascular outcomes in the ORIGIN trial
Gerstein, H. C., Ferrannini, E., Riddle, M. C., Yusuf, S., & ORIGIN Trial Investigators (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13112 · Cited by 11
Bolli, G. B., Porcellati, F., & Meier, J. J. (2020) · Diabetes Care · doi:10.2337/dci20-0038 · Cited by 11
Epidemiology of Type 2 Diabetes
Ronald, C. W., & Tong, P. C. Y. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch5 · Cited by 10
Ahmed, A., Amin, H., Drenos, F., Sattar, N., & Yaghootkar, H. (2023) · Diabetes Care · doi:10.2337/dc23-0855 · Cited by 10
Bolli, G. B., Consoli, A., & Giaccari, A. (2012) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.10.004 · Cited by 10
Blood Pressure Control and Cardiovascular/Renal Outcomes
Dojki, F. K., & Bakris, G. L. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.008 · Cited by 11
brief history of the UK Prospective Diabetes Study: RURY R HOLMAN, FOR THE UKPDS GROUP
Holman, R. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.359 · Cited by 10
Yang, Z., Shen, P., Qu, Y., Xu, L., Li, T., Zhu, Z., Wu, Y., Yu, L., Gao, K., Zhang, X., et al. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101426 · Cited by 11
Gilligan, L., Page, E., Hall, J., Ward, K., Gray, W. K., Briggs, T. W. R., & Rayman, G. A. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111948 · Cited by 9
Humalog (lispro) for type 2 diabetes
Esposito, K., Capuano, A., & Giugliano, D. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.728584 · Cited by 10
Diabetes type 2 diabetes in the elderly – solved and unsolved questions
Саприна, Т. В., & Fajzulina, N. M. (2016) · Diabetes Mellitus · doi:10.14341/dm7884 · Cited by 11
Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial
Bilal, A., & Pratley, R. E. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1086-1 · Cited by 10
Kuo, S., Yang, C., Wu, J., & Ou, H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13525 · Cited by 10
Hyperinsulinaemia and cancer risk: cause and effect?
Kilvert, A., & Fox, C. (2020) · Practical Diabetes · doi:10.1002/pdi.2310 · Cited by 10
Gallagher, E. J., Zelenko, Z., Tobin‐Hess, A., Ulrich, W., Tennagels, N., & LeRoith, D. (2016) · Diabetologia · doi:10.1007/s00125-016-4000-x · Cited by 10
Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease
Oikonomou, E. K., Xenou, M., Zakynthinos, G. Ε., Tsaplaris, P., Lampsas, S., Bletsa, E., Gialamas, I., Kalogeras, K. I., Goliopoulou, A., Gounaridi, M. I., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230703161058 · Cited by 11
Katsanos, A. H., Lee, S. F., Cukierman‐Yaffe, T., Sherlock, L., Terrera, G. M., Canavan, M. D., Joundi, R. A., Sharma, M., Shoamanesh, A., Derix, A., et al. (2023) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2023.100176 · Cited by 11
Candido, R., Nicolucci, A., Larosa, M., Rossi, M. C., Napoli, R., Gabellieri, E., Tortato, E., Rabini, R. A., Crazzolara, D., Lucibelli, L., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.07.025 · Cited by 10
Should Prediabetes be Treated Pharmacologically?
Davidson, M. B. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01449-7 · Cited by 10
Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
Kassem, L. S., Rajpal, A., Barreiro, M. V. E., & Ismail‐Beigi, F. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13446 · Cited by 14
Bedros, J. R., Jermendy, G., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Lengyel, C., Várkonyi, T. T., Winkler, G., & Wittmann, I. (2023) · Diabetologia Hungarica · doi:10.24121/dh.2023.20 · Cited by 18
Use and reporting of restricted randomization: a review
Higham, R., Tharmanathan, P., & Birks, Y. F. (2015) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12408 · Cited by 10
Continuous Subcutaneous Insulin Infusion in Patients With Type 2 Diabetes
Megson, I. L., Treweeke, A. T., Shaw, A., MacRury, S. M., Setford, S. J., Frías, J. P., & Anhalt, H. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815570359 · Cited by 10
Hoogwerf, B. J., Lincoff, A. M., Rodríguez, Á., Chen, L., & Qu, Y. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0393-6 · Cited by 10
Optimizing management of glycaemia
Chatterjee, S., Khunti, K., & Davies, M. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.002 · Cited by 11
Pohlmeier, H., Berard, L., Brulle-Wohlhueter, C., Wu, J., Dahmen, R., NOWOTNY, I. K., & Klonoff, D. C. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816668877 · Cited by 10
A low-carbohydrate survey: Evidence for sustainable metabolic syndrome reversal
Cucuzzella, M. T., Tondt, J., Dockter, N. E., Saslow, L. R., & Wood, T. R. (2017) · Journal of Metabolic Health · doi:10.4102/jir.v2i1.30 · Cited by 10
Anagnostis, P. G., Siolos, P., Christou, K., Gkekas, N. K., Kosmidou, N., Athyros, V. G., & Karagiannis, A. I. (2018) · HORMONES · doi:10.1007/s42000-018-0017-5 · Cited by 10
McFarlane, S. (2018) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/2455-8583.000032 · Cited by 10
Diabetes and Heart Failure: Is it Hyperglycemia or Hyperinsulinemia?
Didangelos, T., & Kantartzis, K. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190408164326 · Cited by 10
BE-SMART (Basal Early Strategies to Maximize HbA1c Reduction with Oral Therapy): Expert Opinion
Bajaj, S., Das, A. K., Kalra, S., Sahay, R. K., Saboo, B., Das, S., Shunmugavelu, M., Jacob, J. J., Priya, G., Khandelwal, D., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0629-z · Cited by 10
Cheng, C., Wang, C., Lin, H.-W., Chang, T.-Y., Lin, H.-J., Chou, C., & Lin, F. (2020) · Scientific Reports · doi:10.1038/s41598-020-62646-z · Cited by 10
Nguyen, J. V., Roseberry, S., Rivas, J. A., & Cauthon, K. A. B. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2021.112 · Cited by 10
Hsu, C., Hsuan, C., Liao, D., Chang, J. K.-J., Chang, A. J.-W., Hee, S., Lee, H.-L., & Teng, S. I. F. (2023) · Life · doi:10.3390/life13041024 · Cited by 11
Hall, G. C., McMahon, A. D., Carroll, D., & Home, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049908 · Cited by 10
Diabetes, Prediabetes and the Survival of Nasopharyngeal Carcinoma: A Study of 5,860 Patients
OuYang, P., Su, Z. Z., Tang, J., Lan, X., Mao, Y., Deng, W., & Xie, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111073 · Cited by 10
Cardiovascular safety of insulin: Between real‐world data and reality
Mannucci, E., & Ferrannini, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12967 · Cited by 10
Perreault, L., Færch, K., & Gregg, E. W. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0899-7 · Cited by 10
Glucose-lowering treatment in cardiovascular and peripheral artery disease
Suades, R., Cosentino, F., & Badimón, L. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.03.001 · Cited by 11
Vargas‐Uricoechea, H., & Pablo, F. J. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.001 · Cited by 10
Advances in managing type 2 diabetes: challenging old paradigms and developing new ones
Sattar, N. A. (2014) · F1000Prime Reports · doi:10.12703/p6-42 · Cited by 9
Metabolic drivers of MASLD and MASH: from hormonal imbalance to fibrosis
Gastaldelli, A., Scoditti, E., & Macedo, M. P. (2026) · Diabetologia · doi:10.1007/s00125-026-06774-7 · Cited by 11
Bramlage, P., Seufert, J., & Pegelow, K. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s54362 · Cited by 9
Kawamori, R., Node, K., Hanafusa, T., Atsumi, Y., Naito, Y., & Oka, Y. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-131 · Cited by 9
Cai, X., Lin, C., Yang, W., Dagogo-Jack, S. E., & Ji, L. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107980 · Cited by 9
Ye, W., Ding, X., Putnam, N. M., Farej, R., Singh, R., Wang, D., Kuo, S., Kong, S. X., Elliott, J., Lott, J. P., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108180 · Cited by 10
Bioactive oxylipins in type 2 diabetes mellitus patients with and without hypertriglyceridemia
Xiao, Y., Pietzner, A., Rohwer, N., Jung, A., Rothe, M., Weylandt, K. H., & Elbelt, U. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1195247 · Cited by 9
Perioperative Considerations for Patients on Semaglutide
Pai, S., Smith, M. A., Beam, W. B., & Harbell, M. W. (2024) · Current anesthesiology reports · doi:10.1007/s40140-024-00611-6 · Cited by 10
An overview of insulin therapy for the non‐specialist
Home, P. D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16280 · Cited by 11
Svensson, A., Miftaraj, M., Franzén, S., & Eliasson, B. (2017) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-017-0043-2 · Cited by 9
Insulin therapy for type 2 diabetes – are we there yet? The d-Nav® story
Hodish, I. (2018) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0056-5 · Cited by 9
Nakanishi, S., Iwamoto, M., Kamei, S., Hirukawa, H., Shimoda, M., Tatsumi, F., Kohara, K., Obata, A., Kimura, T., Kinoshita, T., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9334-17 · Cited by 9
Are newer insulin analogues better for people with Type 1 diabetes?
Misra, S., & Mathieu, C. (2018) · Diabetic Medicine · doi:10.1111/dme.13891 · Cited by 9
Prediabetes: lifestyle, pharmacotherapy or regulation?
Shaw, J. E. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819863020 · Cited by 9
Majumder, A., RoyChaudhuri, S., & Sanyal, D. (2019) · Cureus · doi:10.7759/cureus.6191 · Cited by 9
Mehta, A., Bhattacharya, S., Estep, J. D., & Faiman, C. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2020.04.005 · Cited by 9
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
Novodvorský, P., & Haluzı́k, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1978974 · Cited by 9
Westall, S., Narayanan, R. P., Watmough, S., Irving, G. J., Furlong, N. J., McNulty, S., Bujawansa, S., & Hardy, K. J. (2022) · Clinical Medicine · doi:10.7861/clinmed.2021-0764 · Cited by 12
Nwosu, B. U. (2022) · Endocrines · doi:10.3390/endocrines3030045 · Cited by 10
Kabadi, U. M. (2015) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2015.54026 · Cited by 9
Diabetes and cancer: Could vitamin D provide the link?
Ahmad, S., Chowdhury, T. A., & Boucher, B. J. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.10.005 · Cited by 9
Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?
Krentz, A. J., & Hompesch, M. (2014) · Pharmaceutical Medicine · doi:10.1007/s40290-014-0053-7 · Cited by 9
Gitt, A. K., Bramlage, P., Schneider, S., & Tschöpe, D. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0172-9 · Cited by 10
Mori, Y., Chiang, S., Bendeck, M. P., & Giacca, A. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00320.2015 · Cited by 9
Currie, C. J., Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Voss, B., Rajpathak, S. N., Alemayehu, B., Peters, J. R., & Engel, S. S. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13155 · Cited by 9
Ruiz‐García, A., Arranz-Martínez, E., Merchante, I. M., Fuster, V. P., Tamarit, J. J., Trias, F., Pintó, X., & Ascaso, J. F. (2018) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.06.006 · Cited by 12
Lau, E. S. H., Salem, A. M. H., Chan, J. C. N., So, W. Y., Kong, A. P. S., Lamotte, M., & Luk, A. O. Y. (2019) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-019-0180-9 · Cited by 9
A comprehensive approach to type 2 diabetes mellitus – A recommendation document
Reyes‐García, R., Moreno-Pérez, Ó., Pérez, C. T., Fernández‐García, D., Bellido, V., Casares, M. L. D. L. T., Rozas-Moreno, P., Fernández‐García, J. C., Martínez, A. M., Martín, J. E.-S., et al. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.10.013 · Cited by 11
Tibaldi, J. M., Mercado, M. E., & Strong, J. L. (2020) · Clinical Diabetes · doi:10.2337/cd20-0014 · Cited by 10
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.541699 · Cited by 9
The current schemes of insulin therapy: Pro and contra
Riddle, M. C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108817 · Cited by 10
Role and application of hysterosalpingography and Fallopian tube recanalization.
Mallarini, G., & Saba, L. (2010) · PubMed · Cited by 9
Lorenzoni, V., Baccetti, F., Genovese, S., Torre, E., & Turchetti, G. (2017) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s141477 · Cited by 10
Metadata
- Authors
- The ORIGIN Trial Investigators
- Affiliations
- Population Health Research Institute (CA)
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 319-328
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1975663485
- Semantic Scholar
- 695c6a8e398d66ae418b143a3491ad91d28443bb
- Cited by
- 1,636
- References
- 29
- Citations by year
- 2026: 34 · 2025: 41 · 2024: 76 · 2023: 86 · 2022: 82 · 2021: 108 · 2020: 101 · 2019: 139 · 2018: 155 · 2017: 152 · 2016: 155 · 2015: 132 · 2014: 168 · 2013: 147 · 2012: 53
- FWCI
- 128.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- University of Oxford
- AFA Försäkring
- Hjärt-Lungfonden
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- basal insulin, insulin glargine, impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, cardiovascular outcomes, myocardial infarction, stroke, heart failure, omega-3 fatty acids, hypoglycemia, weight gain, cancer risk, microvascular outcomes, cardiovascular risk factors, revascularization, hospitalization, new-onset diabetes
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Fasting, Female, Follow-Up Studies, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
